Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Myotrophin NDA filing is based on two clinical trials previously discussed by FDA committee.

Executive Summary

CEPHALON MYOTROPHIN NDA FILED FEB. 11 FOR AMYOTROPHIC LATERAL SCLEROSIS (Lou Gehrig's disease) based on the two pivotal trials previously reviewed by FDA's Peripheral & Central Nervous System Drugs Advisory Committee in June as part of the company's request for a Treatment IND. At the time, FDA and the committee agreed that Cephalon's second trial, conducted in Europe, failed to confirm the results of the first. Members of the committee suggested that an additional trial would be required for the application to be approved ("The Pink Sheet" June 17, 1996, p. 9).
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel